Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicentric, Double Blind Study to Assess the Efficacy of Xylka® (Baclofen) at the Target Dosage of 180mg/Day Compared to Placebo, for Maintenance of Abstinence in Alcohol Dependent Patients

NCT01738282 is registered in ClinicalTrials.gov with Ethypharm as lead sponsor.

NCT NCT01738282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01738282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicentric, Double Blind Study to Assess the Efficacy of Xylka® (Baclofen) at the Target Dosage of 180mg/Day Compared to Placebo, for Maintenance of Abstinence in Alcohol Dependent Patients
Lead sponsor
Ethypharm
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2012
Completion date
July 31, 2014
Enrollment
316 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

alcohol dependence